Nurix Therapeutics Inc (NRIX) Stock Analysis

Nurix Therapeutics Inc (NRIX) is a publicly traded company in the HEALTHCARE sector. It trades at $16.37, carries a market capitalization of $1.80B. This page summarizes the public market data, fundamentals, and frequently asked questions for NRIX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Nurix Therapeutics Inc currently has a Neutral sentiment score of 0.14.

About Nurix Therapeutics Inc

Nurix Therapeutics, Inc. is a San Francisco-based biopharmaceutical company focused on the discovery and development of novel small molecule therapies for cancer and immune disorders. Utilizing its proprietary drug discovery platform, Nurix pioneers targeted protein degradation to develop innovative treatment options aimed at enhancing patient outcomes in oncology and immunology. With a strong commitment to advancing cutting-edge therapeutics, Nurix is well-positioned as a compelling investme...

GNG Research Analysis

GNG Research scores Nurix Therapeutics Inc (NRIX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NRIX.

Frequently Asked Questions

Does NRIX pay dividends?

Nurix Therapeutics Inc (NRIX) does not currently pay a regular dividend.

What is NRIX's market cap?

Nurix Therapeutics Inc (NRIX) has a market capitalization of $1.80B with a current stock price of $16.37.